Medical Device Labeling
& Product Review
FDA medical device labeling requirements now operate alongside the Quality Management System Regulation (QMSR), effective February 2, 2026. FDA Registration Assistance reviews labels, packaging, IFU content, UDI requirements, and labeling-control documentation against current U.S. requirements before market or after a material change.
What FDA Medical Device Labeling Compliance Covers
Medical device labeling compliance is broader than checking artwork. General requirements are found in 21 CFR Part 801, while current QMSR labeling and packaging controls are addressed in 21 CFR § 820.45 and applicable ISO 13485:2016 requirements incorporated by reference. Depending on the device, UDI requirements under Parts 801 and 830, prescription-device labeling, IVD labeling, radiation-emitting product requirements, and device-specific special controls may also apply.
FDA Registration Assistance reviews the materials applicable to your device and flags inconsistencies between the label, IFU, intended use, UDI/GUDID data, applicable premarket authorization, and labeling-control records. The goal is to identify corrections before labels are printed or products enter U.S. commerce.
- General device labeling reviewed under 21 CFR Part 801
- Current QMSR labeling and packaging controls reviewed under 21 CFR § 820.45
- UDI applicability and GUDID consistency reviewed where applicable
- IFU and applicable cleared/approved indications checked for consistency
- Written findings and corrective recommendations provided
Our Medical Device Labeling & Product Review Services
A focused review of the label, packaging, IFU, UDI elements, and applicable quality-system controls, tailored to the device's classification, intended use, and U.S. regulatory pathway.
Label Content & Integrity Review
We review required label statements, responsible-firm identification, warnings, directions for use, readability, and whether the label is designed to remain legible and suitable under customary conditions of processing, storage, handling, distribution, and use.
UDI & GUDID Consistency Review
Where UDI requirements apply, we review the displayed UDI structure, package-level identification, date formatting, applicable DI/PI elements, and consistency with the information that should appear in GUDID.
QMSR Labeling-Control Review
We review applicable labeling and packaging procedures against current 21 CFR § 820.45 and the QMSR framework, including accuracy checks, documented release, storage, operations, and controls intended to prevent labeling or packaging mix-ups.
Packaging, IFU & Change-Control Review
We review packaging statements and IFU content for consistency with intended use and applicable authorization, and flag changes that may require additional regulatory assessment, including analysis under FDA's guidance on when a new 510(k) may be needed.
Trusted FDA Medical Device Labeling Review Specialists
Supporting U.S. and international device companies with labeling, packaging, UDI, and regulatory review under current FDA requirements.
How Our Medical Device Labeling Review Service Works
A four-step workflow to review your medical device labeling against current U.S. FDA requirements.
Submit Labels & Device Information
Provide current label artwork, packaging, IFU, product code/classification, UDI information if applicable, and relevant clearance/approval or exemption details.
Regulatory Review Conducted
We review the materials against applicable Part 801 requirements, QMSR § 820.45 controls, UDI/GUDID requirements, and device-specific rules or authorization conditions.
Written Findings Delivered
You receive a clear compliance review identifying observed gaps, recommended corrections, and items that require additional information or device-specific regulatory analysis.
Corrections & Re-Review Support
We support implementation of labeling corrections and can re-review revised artwork or assess future material changes before the updated labeling is used.
Complete FDA Medical Device Compliance Solutions
We offer a full range of FDA medical device compliance services — from establishment registration and device listing to U.S. Agent services, QMS support, and annual renewals.
Medical Device Establishment Registration
Register or renew a covered medical device establishment with FDA and coordinate related listing requirements.
Medical Device Listing
Prepare and maintain medical device listings associated with a registered establishment and applicable product codes.
Medical Device Labeling & Product Review
Ensure your medical device labels and product documentation meet FDA labeling requirements — reviewed by experienced FDA regulatory specialists.
Medical Device DUNS Request Assistance
Assistance obtaining or resolving a DUNS identifier used in FDA medical device registration workflows.
Medical Device U.S. Agent Services
U.S. Agent representation for foreign medical device establishments subject to FDA's foreign-establishment requirements.
Medical Device Listing Certificate
Request a professional listing-verification document prepared from applicable FDA registration and listing records. It is not an FDA-issued certificate or FDA approval.
QMSR / cGMP Support
Support for medical-device quality management systems under FDA's current QMSR framework and applicable ISO 13485:2016 requirements.
Medical Device Annual Establishment Renewal
Annual establishment-registration renewal support during FDA's October 1 through December 31 renewal period.
Import Alert & Device Detention Resolution
Case-specific assistance for FDA medical device detention, refusal, or Import Alert matters.
Laser Accession Report & Submission
Prepare the FDA Laser Product Report / Radiation Safety Product Report, coordinate CDRH submission, and follow the accession number for applicable laser products.
What Current FDA Labeling & Packaging Controls Require
The exact obligations depend on the device, but a compliant review should address the following core areas under Part 801, QMSR, UDI rules, and the device's applicable marketing authorization.
Maintain Documented Labeling & Packaging Procedures
Under current § 820.45, manufacturers must document and maintain procedures describing activities that ensure labeling and packaging integrity, inspection, storage, and operations, together with applicable ISO 13485:2016 controls.
Examine Labeling & Packaging for Accuracy
Before release or storage where applicable, manufacturers must examine labeling and packaging for accuracy, including the correct UDI or other device identification, expiration date, storage instructions, handling instructions, and additional processing instructions when applicable.
Apply UDI Requirements When Applicable
Where the UDI rule applies, the label and device packages must bear a UDI in the required form unless an exception, alternative, or specific FDA enforcement policy applies. Device-specific UDI applicability should be confirmed before artwork is finalized.
Maintain Accurate GUDID Data
Labelers subject to GUDID requirements must submit required device identification data and maintain the record when reportable information changes. The update timeline depends on the type of change and the applicable Part 830 provision.
Prevent Labeling & Packaging Mix-Ups
Labeling and packaging operations must be controlled to prevent mix-ups, including inspection before use to assure the correct labeling and packaging are used for the correct device.
Protect Label & Package Integrity
Procedures should address conditions of processing, storage, handling, distribution, and, as appropriate, use so labeling and packaging remain suitable for their intended purpose.
Document Label Release & Inspection Results
Current § 820.45 requires documented release of labeling for use and documentation of labeling/packaging inspection results in accordance with the QMSR's incorporated record-control requirements.
Assess Material Labeling Changes
Changes to indications for use, warnings, users, environment of use, or other labeling elements may require additional regulatory analysis. For 510(k)-cleared devices, FDA's change guidance should be used to determine whether a new 510(k) is likely required.
Medical Device Labeling & Product Review vs 510(k) Premarket Notification
A professional labeling review and an FDA 510(k) serve different purposes. A labeling review evaluates compliance; a 510(k) is a premarket submission reviewed by FDA when required.
| Attribute | Medical Device Labeling & Product Review | 510(k) Premarket Notification |
|---|---|---|
| Who Performs It | Manufacturer, qualified internal team, or regulatory consultant | Manufacturer submits; FDA reviews the 510(k) |
| What It Represents | Compliance review of labels, packaging, IFU, UDI/GUDID and applicable QMSR controls | Premarket submission supporting substantial equivalence to a legally marketed predicate |
| Regulatory Basis | 21 CFR Part 801; 21 CFR § 820.45/QMSR; Parts 801/830 UDI rules; device-specific requirements | FD&C Act § 510(k) and 21 CFR Part 807 Subpart E |
| Primary Function | Identify labeling and packaging compliance gaps and assess consistency with applicable authorization | Obtain FDA clearance before marketing when a new 510(k) is required |
| FDA Decision? | No. A consultant review is not FDA clearance, approval, certification, or authorization. | Yes. FDA issues a substantial-equivalence determination when the 510(k) is cleared. |
| When Needed | As part of premarket readiness and change control whenever labeling or packaging must comply with applicable FDA requirements | For devices subject to 510(k) requirements and for certain significant changes to a previously cleared device |
A labeling review does not replace a required 510(k), and a cleared 510(k) does not eliminate ongoing labeling obligations. Proposed labeling is part of a 510(k), and later labeling changes may need a new 510(k) analysis depending on the nature and risk of the change.
In-House Labeling Review vs FDA Registration Assistance
Manufacturers may review labeling internally. The practical difference is whether the reviewer has current device-specific regulatory expertise, a documented methodology, and enough independence to catch issues before release.
| Attribute | DIY / In-House Review | Recommended FDA Registration Assistance |
|---|---|---|
| Cost | No external service fee; internal RA/QA time and change-control resources | $249 USD per product review |
| Regulatory Coverage | Depends on the internal team's familiarity with Part 801, QMSR § 820.45, UDI/GUDID, and device-specific requirements | Focused FDA device-labeling review using current regulatory sources and the device's classification/pathway |
| Independence | Internal reviewers may be close to the original artwork or assumptions | Independent second review can identify inconsistencies before release |
| Documentation | Depends on the company's internal checklist and records | Written compliance findings and recommended corrective actions |
| Change Analysis | Internal team must determine whether a change affects UDI/GUDID, intended use, or premarket authorization | Review flags changes that may require additional regulatory assessment, including 510(k)-change analysis |
| Best Fit | Organizations with experienced device RA/QA personnel and mature labeling controls | Companies wanting an additional FDA-focused review before launch, import, printing, or a material change |
FDA does not require companies to hire an outside labeling reviewer. The manufacturer remains responsible for compliance. A professional review adds an independent FDA-focused assessment and written findings before the labeling is released.
Self-Review (Free) vs Professional Labeling & Product Review
There is no FDA government fee for a company to review its own labeling. The choice is between self-review and paying for an independent regulatory review.
| Attribute | Self-Review / Friend / Generic Consultant | Recommended FDA Registration Assistance |
|---|---|---|
| Government Fee | $0 for self-review | $0 FDA government fee for the review; $249 professional service fee |
| Advantages | No external cost; direct internal control; immediate access to product-development information | Independent FDA-focused review, written findings, UDI/GUDID consistency check, and documented recommendations |
| Trade-Offs | Quality depends on internal regulatory expertise and review discipline | Requires providing current artwork and sufficient device/regulatory information |
| Best For | Experienced in-house RA/QA teams with mature labeling controls | Manufacturers, specification developers, relabelers, or import-facing teams that want an additional compliance check |
Self-review can be appropriate for capable in-house regulatory teams. An outside review is most useful when the company wants a second set of eyes on required label elements, UDI applicability, IFU consistency, QMSR controls, or material labeling changes.
Key Medical Device Labeling Terms You Should Know
A working knowledge of these FDA terms helps manufacturers, RA/QA leads, and importers navigate medical device labeling compliance under 21 CFR Parts 801, 820, and 830.
Why Medical Device Labeling Most Often Fails FDA Review
These are common areas where device labeling can become noncompliant or inconsistent with the manufacturer's regulatory records. The regulatory consequence depends on the device and the facts.
UDI Missing, Incorrect, or Inapplicable Logic
A UDI error can arise from an incorrect DI, missing required AIDC/plain-text presentation, package-level errors, or incorrectly assuming an exception applies. UDI applicability should be confirmed for the specific device.
Label or Package Does Not Remain Suitable
Labels and packaging should remain suitable under customary processing, storage, handling, distribution and use. Sterilization or environmental exposure may require device-specific verification.
IFU or Claims Drift From Authorized Intended Use
Changes to indications, users, environment of use, warnings, or claims can create inconsistency with a cleared or approved device and may require additional regulatory analysis.
Responsible-Firm Identification Is Incorrect
Part 801 generally requires the label to identify the manufacturer, packer, or distributor and to qualify the relationship when the named firm is not the manufacturer.
Labeling/Packaging Procedures Are Incomplete
Current QMSR § 820.45 requires documented procedures addressing labeling and packaging integrity, inspection, storage and operations, with accuracy checks and documented release.
Required Quality Records Are Missing
FDA may review QMS records during inspection. Labeling release, inspection, complaint, change-control and other applicable records should support the firm's actual labeling process.
Labeling or Packaging Mix-Ups
Using the wrong label, version, package, or UDI for a device can create misbranding and quality-system issues; QMSR requires controls intended to prevent such mix-ups.
GUDID and Label Data Do Not Match
Where GUDID requirements apply, public device identification data should be maintained consistently with the marketed device and current label.
Frequently Asked Questions — Medical Device Labeling & Product Review
Find answers to the most common questions about FDA Medical Device Labeling & Product Review, annual renewal requirements, and how FDA Registration Assistance helps device companies stay compliant.
What regulation governs FDA medical device labeling control?
General medical device labeling requirements are primarily in 21 CFR Part 801. Since February 2, 2026, FDA's current Quality Management System Regulation (QMSR) applies under 21 CFR Part 820, with device labeling and packaging controls specifically addressed in § 820.45. UDI requirements are found in 21 CFR Part 801 Subpart B and Part 830. Device-specific rules may also apply.
Who must comply with FDA medical device labeling requirements?
The responsible regulated firms must ensure labeling for devices marketed in the United States complies with applicable FDA requirements. Depending on the activity and labeling role, this can include manufacturers, specification developers, repackagers, relabelers, packers, and distributors. The exact obligations depend on the device and the firm's role.
What does current 21 CFR § 820.45 require for labeling and packaging controls?
Current § 820.45 requires manufacturers to document and maintain procedures that address labeling and packaging integrity, inspection, storage, and operations. It also requires examination for accuracy before release or storage where applicable, documented release of labeling for use, and controls intended to prevent labeling and packaging mix-ups. These requirements operate with applicable ISO 13485:2016 provisions incorporated by the QMSR.
What is a Unique Device Identifier (UDI) and is it required on labels?
A UDI is an identifier used to identify a medical device through distribution and use. Many devices must bear a UDI on the label and device packages and have specified information submitted to GUDID, but exceptions, alternatives, direct-marking rules, and FDA compliance policies apply. UDI applicability should be confirmed for the specific device before artwork is finalized.
What replaced the old DHR and DMR terminology under QMSR?
The former QSR contained specific Device History Record (DHR) and Device Master Record (DMR) provisions. Under the QMSR effective February 2, 2026, FDA incorporated ISO 13485:2016 and reorganized Part 820. Manufacturers still must maintain appropriate product and quality records, but the current framework uses ISO 13485 concepts such as the medical device file and control of records rather than the old Part 820.181/820.184 structure.
What information must appear on a medical device label?
Required label content depends on the device. General Part 801 requirements include responsible-firm identification and other applicable statements; many devices also require adequate directions for use or qualify for a prescription-device exemption, UDI information where applicable, and device-specific warnings or statements. IVDs, radiation-emitting products, OTC devices, prescription devices, and other categories may have additional requirements.
What are the consequences of non-compliant medical device labeling?
Noncompliant labeling can make a device misbranded and may lead to FDA inspection observations, warning letters, recalls or corrections, detention or refusal of imported devices, seizure, injunction, or other enforcement depending on the violation and circumstances.
Does FDA require written labeling and packaging procedures under QMSR?
Yes. Current 21 CFR § 820.45 requires manufacturers to document and maintain procedures that provide a detailed description of activities used to ensure labeling and packaging integrity, inspection, storage, and operations. The section also includes accuracy, release-documentation, and mix-up-prevention requirements.
What does label integrity mean under current FDA requirements?
Labeling and packaging controls should account for customary conditions of processing, storage, handling, distribution, and, as appropriate, use. The practical objective is that the correct labeling remains suitable and legible for its intended purpose and does not become compromised through normal conditions.
Can FDA Registration Assistance review labels for foreign device manufacturers?
Yes. The service is available to foreign and domestic medical device companies. Foreign manufacturers placing devices into U.S. commerce are subject to applicable U.S. labeling, UDI, registration, listing, and quality-system requirements regardless of where the device is manufactured.
What is the difference between device labeling and device packaging?
A label is written, printed, or graphic matter on the immediate device container, while 'labeling' is broader and can include labels and other written, printed, or graphic material accompanying the device. Packaging is the physical container or packaging system. FDA's current § 820.45 addresses both labeling and packaging controls.
Does labeling compliance apply to device Instructions for Use (IFU)?
Yes. Instructions for Use can constitute device labeling and must be consistent with applicable intended use, indications, warnings, precautions, contraindications, and directions for use. For devices with FDA clearance or approval, the IFU should also be assessed for consistency with the authorized labeling.
How much does a medical device labeling review cost?
FDA Registration Assistance charges $249 per product review for Medical Device Labeling & Product Review services. This is a professional service fee; FDA does not charge a separate government fee simply for a company to perform or obtain a labeling compliance review.
What documents should I provide for a labeling review?
Provide the current label artwork, all package levels, Instructions for Use, product code and device classification, intended use, applicable 510(k), De Novo, PMA or exemption information, UDI/GUDID data if applicable, and any labeling or packaging procedures you want included in the QMSR review.
Can FDA Registration Assistance review labeling before a 510(k) submission?
Yes. Proposed labeling is an important part of a 510(k). FDA recommends that the indications for use and proposed labels, IFU, package inserts, service manuals, and relevant promotional material be consistent with the submission. A pre-submission labeling review can identify inconsistencies before filing.
Does FDA Registration Assistance assist with the full medical device compliance process?
Yes. Related services include establishment registration, device listing, U.S. Agent service, DUNS assistance, labeling and product review, QMSR support, annual registration renewal, professional listing-verification documents, and Import Alert or detention assistance.
What exactly is included in the $249 Medical Device Labeling & Product Review fee?
The $249 per-product review covers one device's label and packaging review, applicable IFU review, required-label-element assessment, UDI applicability and displayed UDI/GUDID consistency review where relevant, assessment of applicable § 820.45 labeling and packaging controls, and a written set of findings and recommended corrections. Additional regulatory submissions or extensive QMS development are separate services.
Can a friend, in-house staffer, or unrelated party perform the medical device labeling review instead?
FDA does not require a company to hire an outside labeling consultant. A qualified internal employee or authorized third party may review labeling, but the regulated firm remains responsible for compliance. An outside review is useful when the company wants an independent FDA-focused check before release.
What happens if FDA identifies non-compliant labeling on my medical device?
FDA's response depends on the nature and significance of the issue. Possible outcomes include an inspection observation, warning letter, request for correction, recall activity, import detention or refusal, seizure, injunction, or other enforcement authority. Corrective action should be tailored to the specific violation.
How do I update or change labeling on an existing FDA device?
Use your change-control process to evaluate the new labeling against Part 801, QMSR controls, UDI/GUDID requirements, and the device's marketing authorization. Some changes may require GUDID updates, revised listing information, or a new regulatory submission. For a 510(k)-cleared device, FDA's guidance on changes to an existing device should be used to determine whether a new 510(k) is likely required.
Does a software-only medical device (SaMD) need FDA-compliant labeling?
Yes, if the software is a regulated medical device. The exact presentation may differ from a physical device, but software-device labeling can include on-screen information, user documentation, electronic instructions, websites or other materials accompanying the device. The content must meet the requirements applicable to that software device and its intended use.
Do I need a UDI on a Class I exempt medical device?
Not always. FDA provides UDI exceptions and enforcement policies for certain Class I and unclassified devices. For example, FDA states that Class I devices exempt from device CGMP requirements are excepted from UDI requirements under 21 CFR 801.30(a)(2). UDI status should be checked against the specific product code, exemption, and current FDA policy.
Are OTC medical devices held to the same labeling rules as prescription devices?
Both are subject to FDA labeling requirements, but they are not identical. OTC devices generally need adequate directions for use that a layperson can follow, while prescription devices may qualify for the exemption in 21 CFR 801.109 when the required conditions are met and must bear appropriate prescription labeling and information for safe use.
Can I sell my medical device online without FDA-compliant labeling?
No sales channel removes FDA labeling obligations. If a product is a regulated medical device offered in U.S. commerce, the applicable FDA labeling, authorization, registration/listing, and UDI requirements still apply. Online marketplaces may also request their own compliance documentation.
Does my contract manufacturer's name or address need to appear on the medical device label?
Not necessarily. Under 21 CFR 801.1, the label must identify the manufacturer, packer, or distributor. If the named firm is not the manufacturer, the relationship generally must be qualified with wording such as 'Manufactured for' or 'Distributed by.' The correct presentation depends on which firm is named on the label and its role.
How often should I have my medical device labeling re-reviewed?
FDA does not impose a universal annual third-party labeling-review requirement. Re-review should occur when the label, IFU, packaging, intended use, warnings, UDI, product configuration, authorization, or applicable requirements materially change, and at any additional intervals defined by the manufacturer's own quality system and risk controls.
What is the difference between misbranding and adulteration for a medical device?
Misbranding generally concerns labeling, representation, directions for use, registration/listing, and other statutory labeling-related requirements under FD&C Act section 502. Adulteration under section 501 concerns separate statutory conditions, including certain manufacturing or premarket-approval violations. A device can be misbranded, adulterated, or both depending on the facts.
Can I use electronic Instructions for Use (eIFU) instead of paper IFU?
Do not assume that 21 CFR 801.109 creates a general eIFU option for every prescription device. Whether electronic instructions can replace paper depends on the device, the applicable regulation or authorization, any device-specific guidance, and the labeling that FDA cleared or approved. Some devices have FDA-authorized electronic IFU, but the analysis is device-specific.
How do I verify my medical device labeling and FDA records?
Use the FDA Establishment Registration & Device Listing database for registration/listing information, AccessGUDID for public UDI/DI data, and the appropriate FDA premarket database for 510(k), De Novo, PMA, or other authorization information. A labeling review should compare public regulatory records with the current marketed device where applicable.
If my foreign facility address changes, do I need to update the medical device label?
If the address of the manufacturer, packer, or distributor identified on the label changes, the label should be reviewed for accuracy under Part 801. The company should separately assess any required establishment-registration, U.S. Agent, listing, and GUDID updates. The exact filing timeline depends on the record and type of change.
Get Your Medical Device Labels Reviewed Today
Send us your current label artwork, packaging, IFU, and basic device information. We will review the materials against applicable FDA labeling, QMSR, and UDI requirements and tell you what should be corrected before release.
Thank You for Reaching Out!
We've received your message and will get back to you within 24 hours. If you need immediate assistance, please call us directly.